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Parkinsonism and Related Disorders 19 (2013) 864e868Contents lists availableEditor’s comment: Dementia develops frequently during the advanced phases of Parkinson’s disease, and is termed Parkinson’s disease
dementia, or PDD. The pathological bases of this devastating complication are probably multifactorial and, currently, the objective of inten-
sive investigations.
In this issue, Horvath et al. aim to dissect the role of four suspects in the development of PDD: the cortical alpha-synuclein pathology, tau
pathology, beta-amyloid pathology, and cerebrovascular pathology, in a large series of brains from 155 PD patients (109 with PDD),
collected at the Geneva University Brain Bank.
In a multivariate statistical analysis, the cortical alpha-synuclein pathology emerged as the most important substrate of dementia, with an
odds ratio of 4.2. The cortical tau pathology burden was also an independent signiﬁcant contributor, though with a lower odds ratio of 1.6.
Thus, this study conﬁrms the cortical alpha-synucleinopathy as the main pathological substrate of PDD, but also points to an important role
for the tau pathology, particularly, perhaps, in the most severe stages of PDD. Furthermore, the study highlights that the burden of the
cortical alpha-synuclein, tau, and beta-amyloid lesions appear to be inter-correlated; this fact, in keeping with data from experimental
studies, suggests synergistic mechanisms in the aggregation of different proteins during the neurodegenerative diseases.
The study by Horvath et al., one of the largest of this kind, also reminds us of the richness and the great opportunities offered by the exist-
ing brain banks of patients with neurological disorders, of which the Geneva University Brain Bank is a prestigious representative.
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The aim of our study was to establish the contribution of distinct pathological aggregates (cortical Lewy
bodies (LB), neuronal tau-inclusions and b-amyloid plaque (Ab) deposition) in dementia related to
Parkinson’s disease (PD) in a large autopsy cohort.
We studied the brains of 155 PD patients, 109 of whom were clinically demented. The total LB score,
the Braak stages for neuroﬁbrillary tangles (NFT) and the Thal phases for Ab deposition were assessed in
each case, according to previously published guidelines.
All the three lesion types were more abundant in the demented PD group, compared to the non-
demented PD group, but neocortical LB pathology was the most important substrate of dementia. A
signiﬁcant correlation was found between the severity of Ab phases, NFT stages and cortical LB scores. In
a subgroup of severely demented PD patients, cortical tau burden was much higher than in the rest of the
group. Extensive cortical NFTs associate unavoidably with dementia. Some patients remain cognitively
intact despite high cortical LB score. In conclusion, our data strongly support a combining, yet distinct
role of neocortical LBs and tau deposits.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Geneva University Hospitals
entil 4, 1211 Geneva 14,
80 99.
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Dementia is a common complication of advanced Parkinson’s
disease (PD)with lifetime prevalence as high as 80% after 20 years of
evolution [1]. Since the late 1970’s, cortical Alzheimer’s disease
(AD)-type pathology [2,3] and subcortical noradrenergic, seroto-
ninergic and cholinergic deﬁcits [4,5] have been proposed as license.
Table 1
Demographic and neuropathologic characteristics of demented versus non-
demented PD patients.
Total cohort
(Mean  SD)
PDD group
(Mean  SD)
PDND group
(Mean  SD)
P
valuea
Number of cases 155 109 46 e
Mean age at death
(years)
79.9  7.4 79.4  7.3 81.2  7.3 0.160
Male-to-female ratio 1.09 0.94 1.55 0.218
Hallucination/psychosis 28 (18.1%) 23 (21.1%) 5 (10.8%) 0.130
Mean LB score 5.4  3.1 6.0  3.2 4.1  2.4 <0.001
Number of cases with
LB scores >3
111 (71.6%) 82 (75.2%) 29 (63.0%) 0.172
Number of cases with
LB scores >6
61 (39.3%) 54 (49.5%) 7 (15.2%) <0.001
Number of cases
with types of LBD:
e e e <0.001
brainstem type 30 (19.3%) 16 (14.7%) 14 (30.4%) e
limbic type 64 (41.3%) 39 (35.8%) 25 (54.3%) e
neocortical type 61 (39.3%) 54 (49.5%) 7 (15.2%) e
Mean Ab phase 1.6  1.4 1.8  1.4 1.1  1.2 0.003
Mean Braak NFT stage 1.6  1.6 1.8  1.7 1.0  0.9 0.009
Number of cases
with Braak
NFT scores >3
17 (10.9%) 17 (15.6%) 0 0.003
CVD 25 (16.1%) 17 (15.6%) 8 (17.3%) 0.813
PD: Parkinson’s disease; PDD: Parkinson’s disease with dementia; PDND: PD
without dementia; LB: Lewy body; NFT: neuroﬁbrillary tangle; CVD: cerebrovas-
cular disease; Ab: b-amyloid.
a P value of variables comparing PDD with PDND groups.
Fig. 1. Distribution of LB scores (A), NFT stages (B) and Ab phases (C) among the
demented versus the non-demented PD patients. Each circle represents one case.
PDND: non-demented PD group, PDD: demented PD group. LB: Lewy body; NFT:
neuroﬁbrillary tangle; Ab: b-amyloid.
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(PDD), in addition to frontostriatal dopamine deﬁciency and
vascular changes. More recently, immunohistochemical methods,
especially staining with anti-a-synuclein (aSyn) antibodies allowed
the recognition of cortical Lewy bodies (LBs) and Lewy neurites
(LNs) and of their role in PDD [6e12], althoughmost of these studies
assessed relatively small populations of patients (less than50 cases).
In a larger autopsy series (88 PD patients, 65 demented), published
by Braak et al. [13], cognitive decline correlated with the Braak
neuropathological stages of PD [14]. Compta et al. [15] argued that
the Braak stages may not be sensitive enough and suggested that a
quantitative or semi-quantitative assessment of cortical LB pathol-
ogy would be more informative. There have been also reports of
cases where, despite extensive cortical LBs, patients did not develop
dementia [16]. Some authors have suggested that it is a combination
of aSyn and AD-type pathologies that would best underlie cognitive
decline in PD rather than a single lesion type [15]. A recent studyon a
large cohort of 140 PD patients found that the most signiﬁcant
correlate of dementia was cortical LB/LN pathology, yet AD pathol-
ogy was also abundant in a subset of patients [17].
The aim of our studywas to establish the respective contribution
of each of the three incriminated deposit types (i.e. cortical b-am-
yloid (Ab) plaques, neuronal tau and aSyn inclusions) to dementia in
a large autopsy cohort of patients with advanced PD. The potential
role of cerebrovascular lesions was also assessed.
2. Patients and methods
2.1. Patients with PD
We selected all patients from the Geneva University Brain Bank database in
whom a parkinsonian syndrome had been clinically diagnosed and in whom idio-
pathic PD was neuropathologically conﬁrmed at autopsy (N ¼ 167). All patients had
been hospitalized before death, they died and were autopsied in the Geneva Uni-
versity Hospitals. The presence or absence of dementia was established retrospec-
tively by extensively reviewing the fully archived clinical records and by applying
the DSM-IV criteria retrospectively. It was based on cognitive evaluations made in
the hospital, during the last or a previous hospitalization. Since all patients had
stayed in the hospital before death, in a high proportion of cases, detailedneuropsychological evaluations were performed and well documented in patients’
records but quantiﬁed scales (MMSE, CDR scores etc.) were infrequently performed.
Based on this clinical assessment, patients were sorted into two groups: a PD
with dementia (PDD) group or a PD without dementia (PDND) group. We excluded
patients with a diagnosis of dementia with LB’s or when dementia was documented
Table 2
Factors associated with dementia using univariate and multivariate logistic regres-
sion models.
Variables Univariate Multivariate R2 ¼ 15.5%
Or 95% CI P value R2 (%) Or 95% CI P value
Age 0.96 0.92e1.01 0.164 1.0 0.95 0.89e1.00 0.058
Male sex 0.60 0.30e1.22 0.165 1.0 0.59 0.27e1.28 0.179
LB scores 1.24 1.10e1.40 <0.001 7.1 e e e
LB score >3 1.78 0.84e3.73 0.127 1.2 e e e
LB score >6 5.47 2.25e13.29 <0.001 9.3 4.20 1.67e10.59 0.002
Braak NFT
stages
1.55 1.16e2.07 0.003 5.8 1.60 1.13e2.27 0.009
Braak NFT
stage>3
11.76 1.94 þN 0.003 e e e e
Ab phases 1.50 1.14e198 0.004 4.9 e e e
CVD 0.87 0.34e2.20 0.781 0.0 0.90 0.32e2.51 0.839
LB: Lewy body; NFT: neuroﬁbrillary tangle; CVD: cerebrovascular disease; Ab: b-
amyloid.
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clinical data or lost ﬁles were excluded (N ¼ 12).
We computed basic demographic data, such as gender and age at death, and,
when available, clinical dementia rating (CDR) score, Mini Mental State Examination
(MMSE) score, and presence of hallucinations and psychosis.2.2. Neuropathological assessment
In all cases, idiopathic PDwas conﬁrmed by the presence of LBs in the substantia
nigra. Five cortical regions were taken and embedded in parafﬁn, according to the
ﬁrst Consortium on Dementia with Lewy bodies [18], including the frontal cortex
(Brodmann area 9), the middle temporal gyrus (area 21), the anterior cingulate
cortex (area 24), the parietal cortex (area 40) and the transentorhinal cortex.
Twelve mm thick serial sections were cut and stained consecutively with
hematoxylin-eosin (HE) and with anti-aSyn (Sigma, Saint Louis, Missouri, USA, 1/
1000), anti-tau (Pierce Biotechnology, Rockford, IL USA, 1/1000) and anti-b-amyloid
(4G8; Signet Laboratories, Dedham, MA, USA, 1:2000) antibodies. The severity of
cortical tau pathology was determined according to the Braak staging system of
neuroﬁbrillary tangles (NFT stages) [19]. For a semi-quantitative assessment of
cortical Ab deposition, we used the Thal phases (Ab phases) [20]. To establish the
severity of cortical aSyn pathology, we referred to the Consensus criteria for De-
mentia with Lewy bodies [18] and deﬁned the total LB score and the distribution
type (brainstem, limbic or neocortical type) accordingly. For the assessment of
macroscopic and microscopic vascular lesions, in the absence of consensus diag-
nostic criteria for vascular dementia, we used earlier methods [21]. We retained a
signiﬁcant cerebrovascular disease (CVD) in the presence of multiples brain infarcts,
extended microinfarcts in associative cortical areas or lacunar state of the basal
ganglia or in the thalamus.2.3. Statistical analysis
Binary variables were compared using the Fischer’s exact test. Continuous and
ordinal variables were compared using the ManneWhitney U test. The association of
variables with dementia was assessed using univariate and multiple logistic re-
gressions. The strength of the association between variables was evaluated with the
Spearman correlation coefﬁcient. A p value <0.05 was deﬁned as statistically signiﬁ-
cant. Stata release 12.1was used for data analysis (Stata Corp., College Station, TX, USA).
The study was approved by the ethical committee of the Geneva University
Hospitals. Written permissions have been obtained from all patients or family
members since 2004. For autopsy material dating from before 2004, the ethical
committee authorized the research without written consents.3. Results
From a total of 155 PD cases, 109 (70%) had been clinically
diagnosed with dementia. Demographic and clinical data and the
distribution of different lesion types in the PDD versus PDND
groups are summarized in Table 1 and Fig. 1. A CDR score was
available in 20 demented patients, 13 of which were rated at CDR3
corresponding to severe dementia. Demographic data, in particular
age at death, did not differ between the PDD and the PDND groups
and the CDR3 subgroup.The frequency of reported hallucinations or psychosis was twice
as high in the demented group as in the non-demented group but
this was not statistically signiﬁcant.
Mean LB score, Braak NFT stage and Ab phase were signiﬁcantly
increased in the PDD group compared to the PDND group (Table 1,
Fig. 1). A neocortical type of LB pathology (LB score >6) was
signiﬁcantly more frequent in the PDD group (p < 0.001). A Braak
NFT stage superior to 3 was 100% predictive of dementia (i.e. no
such case was found among PDND patients).
In a subgroup of 13 PDD patients, with documented advanced de-
mentia at CDR3, the mean LB score, the proportion of limbic and
neocortical types of LBpathologyand themeanAbphasewere the same
as in the whole PDD group. However, mean Braak NFT stage was 3.2 in
theCDR3subgroupcomparedto1.8 inthePDDgroupandtheproportion
of patientswithhigh tauburden (BraakNFT>3)wasmuchhigher in the
CDR3 subgroup (46.1%) than in the PDD group (15.6%).
The prevalence of CVD did not differ signiﬁcantly in the
demented versus non-demented group.
The subgroup of patients with reported hallucination or psy-
chosis did not differ from the entire cohort regarding CVD, mean LB
scores, Braak stages for NFT and Ab phases.
The associations between dementia, Braak NFT stages, LB scores
and Ab phases were assessed by logistic regression models (See
Table 2). A neocortical stage of LB (LB score>6) was associated with
the highest odds ratio of dementia (OR ¼ 4.2; p < 0.001), and
increased Braak NFT stages were also independently associated
with dementia (OR ¼ 1.6; p ¼ 0.009) in a multiple logistic regres-
sion model. Association of Ab phases with dementia was signiﬁcant
(OR¼ 1.50; p¼ 0.004) but did not add more predictive information
in the multiple logistic model.
A Braak NFT stage >3 was always associated with dementia
(Univariate exact logistic regression OR ¼ 11.76; p ¼ 0.003).
A signiﬁcant correlation was found between LB scores and Ab
phases (rho ¼ 0.36; p < 0.001), between Braak NFT stages and LB
scores (rho¼ 0.23; p< 0.001) and between Braak NFT stages and Ab
phases (rho ¼ 0.36; p < 0.001), using Spearman correlation.
Of note, seven patients were not demented in spite of a
neocortical type of LB pathology (LB score>6).
4. Discussion
In this study, we found that cortical LB pathology was the most
important pathological substrate of dementia in our large autopsy
cohort, affecting about 50% of demented PD patients and increasing
signiﬁcantly the risk of dementia by an OR superior to 4. This
ﬁnding conﬁrms the key role of cortical LBs in PD-related dementia,
as already highlighted by others [7,9,12,13] including in a very
recently published large study [17]. In addition, neuronal tau pa-
thology (Braak NFT stages) emerged as a signiﬁcant and indepen-
dent determinant of dementia, affecting about 15% of PDD patients
and increasing the risk of dementia by an OR of 1.6. Eighty-ﬁve % of
our demented PD patients had Braak NFT stage <4. This suggests
that high tau burden is not necessary for the development of PD-
related dementia. An extensive cortical Lewy body pathology
alone may be sufﬁcient to cause dementia without high Braak NFT
stage. According to our data, the contribution of tau deposition to
dementia appears less robust than LB pathology, which seems to
contradict the study by Jellinger who found AD-type pathology to
be more important than LBs in a demented PD population [22].
One reason for this apparent discrepancy can be found in the
difference between the two cohorts regarding dementia severity. In
the Jellinger’s study only 44% of the PD cohort was categorized as
demented, which is lower than what is expected, given a lifetime
prevalence of dementia in PD of around 70%. Apparently, they used
more stringent diagnostic criteria for dementia so that their group
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our PDD group. Indeed, their median MMS score was 15/30, indi-
cating advanced cognitive decline. More advanced dementia (CDR3
group) was actually associated with much higher tau burden in our
study as well (See later).
Finally, increased cortical Ab phases were marginally associated
with dementia, as this did not reach signiﬁcance in the multivariate
model. CVD was not a factor determining cognitive decline in our
series, neither in the recent study of Irwin et al. [17], but Jellinger
(in the above mentioned study), found a higher prevalence of CVD
in demented PD patients.
Since AD is the most frequent cause of dementia in the general
population, one can ask whether its occurrence is only coincidental
in an elderly population with PD. Using the neuropathologic criteria
of the National Institute on Aging-Alzheimer’s Association guidelines
[23], combining both Ab plaques and NFT scores for the diagnosis of
AD, 31 patients (20.0%) of our PD cohort fulﬁlled the criteria for AD. In
the entire autopsy cohort of the Geneva University Brain Bank,
consisting of more than 10,000 brains, the prevalence of pathologi-
cally conﬁrmed AD was 15.7% [24]. The difference may suggest that
PD somehow predisposes to AD-type pathological processes or that
both pathologies concur to induce dementia in a relatively high
proportion of PD patients. This is not an age-related effect since the
mean age at death in patients fulﬁlling the criteria of AD was 82.8
years in our PD cohort, and 82.1 years in the whole Geneva cohort,
which is nearly identical. In this line, our study conﬁrms previous
observations that higher Braak tau stages correlate well with cogni-
tive impairment as a Braak NFT stage>3 predicted dementia in 100%
of our cases [25]. Compta et al. [15] also found that lower MMSE
score, reﬂecting more severe dementia, correlated better with the
severity of AD-type pathology thanwith the LB score. However, Braak
et al. [13] found that lower MMSE score correlated with higher Braak
Lewy body stage of PD. Interestingly, in the subgroup of severely
demented PDD patients (CDR3), mean LB score was the same but tau
burdenwasmuch higher than in thewhole PDD group and this again
was not explained by an age-related effect. This observation supports
tau pathology as an independent and aggravating contributor to the
development of severe dementia in PD.
There was a correlation between dementia and the severity of
cortical tau, b-amyloid and aSyn pathology, which is in favor of a
synergistic interaction between aSyn, tau and Ab aggregations, as
suggested by previous studies [7,26e29]. An earlier dementia and
shorter survival was found by Kotzbauer [30], in a subgroup of PD
patients who had b-amyloid plaques in addition to cortical synu-
cleinopathy versus cortical a-synucleinopathy alone.
In our series, 7 non-demented PD patients had an LB score>6,
i.e. a neocortical type of LBD, suggesting that even widespread
cortical LBs do not necessarily result in dementia. Previous authors
[16,28] have also described similar observations. We should, how-
ever, be cautious in interpreting this result, because clinical data
were collected retrospectively. Since formal cognitive testing was
not performed routinely in each case, some dementia cases could
have been overlooked.
Hallucination or psychosis was twice as frequently reported in
the demented population than in the non-demented PD group but
this differencewas not signiﬁcant.We could not identify any type of
pathological lesion correlating with hallucinations or psychosis,
similarly to Sabbagh [31] who did not ﬁnd any difference regarding
hallucinations between demented PD patients with and without
AD-type pathology.
We believe clinicopathological studies assessing individual
lesion types are pivotal to the understanding of the mechanisms
underlying dementia in PD, the more so as protein deposition can
now be studied in vivo using various biomarkers such as aSyn, tau
and Ab levels in the cerebrospinal ﬂuid, apolipoprotein E genotypeand Pittsburgh compound B positron emission tomography. Our
data strongly support a combining, yet distinct role of neocortical
aSyn and tau deposits. We hypothesize that LB pathology may
initiate neuronal dysfunction which, when building up above a
critical threshold, may be sufﬁcient to induce a signiﬁcant cognitive
decline. When present, tau pathology adds a burden to existing
intraneuronal aSyn load, overwhelming already dysfunctional
neurons and networks and promoting patients into overt dementia.
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